HC3-1496
InCode has capitalized on the safe and effective depletion of complement in preclinical models by Cobra Venom Factor (CVF). CVF is a structural analog of the complement protein C3, sharing approximately 50% homology at the protein level. We have developed a product candidate that combines the overall structure of human C3 with the homologous sequence from CVF. This protein, HC3-1496, interacts with complement factor B to form a stable convertase (C3bBb) that enzymatically depletes complement C3, without the downstream activation of C5.
D.C. Fritzinger, B.E. Hew, M. Thorne, et al. (2009). Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Developmental and Comparative Immunology 33:105-116.
D.C. Fritzinger, B.E. Hew, J.Q.Lee, et al. (2008). Advances in Experimental Medicine and Biology, Current Topics in Complement II. 632:282-296.
C.W.Vogel and D.C. Fritzinger (2007) Humanized cobra venom factor: experimental therpeutics for targeted complement activation and complement depeletion. Current Pharmaceutical Design 13(28):2916-2926.